Dimethyl fumarate (DMF) is used in the treatment of MS and psoriasis, and its metabolites (monomethyl fumarate) succinate the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), resulting in decreasing glycolysis and increasing OXPHOS [201,210,211,212]. This evidence concerns the gene GAPDH and psoriasis.